pentetreotide
(ONJXCGCIKIYAPL-MLRSDOHDSA-K)
Structure
- SMILES
- NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)C(=O)N[C@@H]([C@H](O)C)CO)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC(=O)[O-])Cc1c[nH]c2c1cccc2.[111In+3]
- Molecular Formula:
- C63H84InN13O19S2
- Molecular Weight:
- 1502.450
- Log P:
- -3.8906
- Hydrogen Bond Acceptor:
- 33
- Hydrogen Bond Donor:
- 14
- TPSA:
- 553.31
- CAS Number(s):
- N/A
Synonym(s)
1.
pentetreotide
2.
111 In -pentetreotide
3.
111-indium-pentetreotide
4.
In-111 pentetreotide
5.
OctreoScan
6.
OctreoScan 111
7.
indium In 111 pentetreotide
8.
indium ln-111 pentetreotide
9.
indium-pentetreotide
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Intentional drug misuse | FAERS: 17 | US FAERS | |
| 2 | Drug ineffective | FAERS: 11 | US FAERS | |
| 3 | Blood bilirubin abnormal | FAERS: 6 | US FAERS | |
| 4 | Nausea | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 5 | Flushing | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 6 | Accidental exposure | FAERS: 3 | US FAERS | |
| 7 | Blood creatinine abnormal | FAERS: 3 | US FAERS | |
| 8 | Erythema | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Back Pain | FAERS: 2 | US FAERS | |
| 10 | Fatigue | FAERS: 2 | US FAERS | |
| 11 | Injection site pain | FAERS: 2 | US FAERS | |
| 12 | MYELODYSPLASTIC SYNDROME | FAERS: 2 | US FAERS | |
| 13 | Skin lesion | FAERS: 2 | US FAERS | |
| 14 | Thrombocytopenia | FAERS: 2 | US FAERS | |
| 15 | Abdominal Pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 16 | Acute kidney injury | FAERS: 1 | US FAERS | |
| 17 | Asthenia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 18 | Chromaturia | FAERS: 1 | US FAERS | |
| 19 | Dizziness | FAERS: 1 | US FAERS | |
| 20 | Drug administration error | FAERS: 1 | US FAERS | |
| 21 | Dysphonia | FAERS: 1 | US FAERS | |
| 22 | False positive laboratory result | FAERS: 1 | US FAERS | |
| 23 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 24 | Ileus | FAERS: 1 | US FAERS | |
| 25 | Infection | FAERS: 1 | US FAERS | |
| 26 | Injection site extravasation | FAERS: 1 | US FAERS | |
| 27 | Intentional product misuse | FAERS: 1 | US FAERS | |
| 28 | Medication Error | FAERS: 1 | US FAERS | |
| 29 | Mixed liver injury | FAERS: 1 | US FAERS | |
| 30 | Musculoskeletal Pain | FAERS: 1 | US FAERS | |
| 31 | Ocular icterus | FAERS: 1 | US FAERS | |
| 32 | Oropharyngeal pain | FAERS: 1 | US FAERS | |
| 33 | Pallor | FAERS: 1 | US FAERS | |
| 34 | Palpitations | FAERS: 1 | US FAERS | |
| 35 | Pituitary cancer metastatic | FAERS: 1 | US FAERS | |
| 36 | Product use in unapproved indication | FAERS: 1 | US FAERS | |
| 37 | Product use issue | FAERS: 1 | US FAERS | |
| 38 | Sensorimotor disorder | FAERS: 1 | US FAERS | |
| 39 | Tonic clonic movements | FAERS: 1 | US FAERS | |
| 40 | Wrong drug administered | FAERS: 1 | US FAERS | |
| 41 | jaundice | FAERS: 1 | US FAERS | |
| 42 | Injection site erythema | Canada Vigilance: 1 | Canada Vigilance | |
| 43 | Injection site urticaria | Canada Vigilance: 1 | Canada Vigilance | |
| 44 | Pruritus | Canada Vigilance: 1 | Canada Vigilance | |
| 45 | Urticaria | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.